RESUMEN
Current study investigates the immunomodulatory effects of T. stocksianum using mouse model of ovalbumin (OVA)-induced allergic asthma. The mice were treated with methanolic extract, n-hexane, and ethyl acetate fractions for consecutive 7 days along with intranasal challenge. The mRNA expression levels of interleukin-4 (IL-4), IL-5, Aquaporin-1 (AQP1) and Aquaporin-5 (AQP5) were evaluated using reverse transcription polymerase chain reaction. The data showed that T. stocksianum significantly reduced airway inflammation as indicated by reduced inflammatory cell infiltration in lungs, and attenuated total and differential leukocyte counts both in blood and BALF. Expression levels of pro-inflammatory IL-4 and IL-5 in lungs were also found significantly reduced. T. stocksianum significantly reduced pulmonary edema as indicated by reduced lung wet/dry ratio and goblet cell hyperplasia. AQP1 and AQP5 expression levels were also found elevated in treatment groups. In conclusion, T. stocksianum possesses anti-asthmatic activity which may be attributed to reduction in IL-4 and IL-5 expression levels, and elevation in AQP1 and AQP5 expression levels.
Asunto(s)
Acuaporina 1/efectos de los fármacos , Acuaporina 5/efectos de los fármacos , Asma/tratamiento farmacológico , Hipersensibilidad/tratamiento farmacológico , Factores Inmunológicos/farmacología , Inflamación/tratamiento farmacológico , Interleucina-4 , Interleucina-5 , Edema Pulmonar/tratamiento farmacológico , Enfermedades Respiratorias/tratamiento farmacológico , Teucrium , Animales , Asma/inmunología , Modelos Animales de Enfermedad , Femenino , Hipersensibilidad/inmunología , Factores Inmunológicos/administración & dosificación , Inflamación/inmunología , Masculino , Ratones , Ratones Endogámicos BALB C , Extractos Vegetales/administración & dosificación , Edema Pulmonar/inmunología , Enfermedades Respiratorias/inmunologíaRESUMEN
BACKGROUND: Administration of antenatal steroids is standard of care for women assessed to be at imminent risk of preterm delivery. There is a marked variation in antenatal steroid dosing strategy, selection for treatment criteria, and agent choice worldwide. This, combined with very limited optimization of antenatal steroid use per se, means that treatment efficacy is highly variable, and the rate of respiratory distress syndrome is decreased to perhaps as low as 40%. In some cases, antenatal steroid use is associated with limited benefit and potential harm. OBJECTIVE: We hypothesized that individual differences in maternofetal steroid exposure would contribute to observed variability in antenatal steroid treatment efficacy. Using a chronically catheterized sheep model of pregnancy, we aimed to explore the relationship between maternofetal steroid exposure and antenatal steroid treatment efficacy as determined by functional lung maturation in preterm lambs undergoing ventilation. STUDY DESIGN: Ewes carrying a single fetus underwent surgery to catheterize a fetal and maternal jugular vein at 119 days' gestation. Animals recovered for 24 hours before being randomized to either (1) a single maternal intramuscular injection of 2 mL saline (negative control group, n=10) or (2) a single maternal intramuscular injection of 0.25 mg/kg betamethasone phosphate plus acetate (antenatal steroid group, n=20). Serial maternal and fetal plasma samples were collected from each animal after 48 hours before fetuses were delivered and ventilated for 30 minutes. Total and free plasma betamethasone concentration was measured by mass spectrometry. Fetal lung tissue was collected for analysis using quantitative polymerase chain reaction. RESULTS: One animal from the control group and one animal from the antenatal steroid group did not complete their treatment protocol and were removed from analyses. Animals in the antenatal steroid group were divided into a responder subgroup (n=12/19) and a nonresponder subgroup (n=7/19) using a cutoff of partial pressure of arterial CO2 at 30-minute ventilation within 2 standard deviations of the mean value from saline-treated negative control group animals. Although antenatal steroid improved fetal lung maturation in the undivided antenatal steroid group and in the responder subgroup both physiologically (blood gas- and ventilation-related data) and biochemically (messenger ribonucleic acid expression related to fetal lung maturation), these values did not improve relative to saline-treated control group animals in the antenatal steroid nonresponder subgroup. No differences in betamethasone distribution, clearance, or protein binding were identified between the antenatal steroid responder and nonresponder subgroups. CONCLUSION: This study correlated individual maternofetal steroid exposures with preterm lung maturation as determined by pulmonary ventilation. Herein, approximately 40% of preterm lambs exposed to antenatal steroids had lung maturation that was not significantly different to saline-treated control group animals. These nonresponsive animals received maternal and fetal betamethasone exposures identical to animals that had a significant improvement in functional lung maturation. These data suggest that the efficacy of antenatal steroid therapy is not solely determined by maternofetal drug levels and that individual fetal or maternal factors may play a role in determining treatment outcomes in response to glucocorticoid signaling.
Asunto(s)
Betametasona/análogos & derivados , Madurez de los Órganos Fetales/efectos de los fármacos , Glucocorticoides/farmacología , Pulmón/efectos de los fármacos , Animales , Acuaporina 1/efectos de los fármacos , Acuaporina 1/genética , Acuaporina 5/efectos de los fármacos , Acuaporina 5/genética , Betametasona/sangre , Betametasona/farmacología , Análisis de los Gases de la Sangre , Dióxido de Carbono , Canales Epiteliales de Sodio/efectos de los fármacos , Canales Epiteliales de Sodio/genética , Femenino , Madurez de los Órganos Fetales/genética , Glucocorticoides/sangre , Pulmón/metabolismo , Pulmón/fisiopatología , Rendimiento Pulmonar/efectos de los fármacos , Espectrometría de Masas , Intercambio Materno-Fetal , Presión Parcial , Atención Perinatal , Reacción en Cadena de la Polimerasa , Embarazo , Nacimiento Prematuro , Atención Prenatal , Proteína A Asociada a Surfactante Pulmonar/efectos de los fármacos , Proteína A Asociada a Surfactante Pulmonar/genética , Proteína B Asociada a Surfactante Pulmonar/efectos de los fármacos , Proteína B Asociada a Surfactante Pulmonar/genética , Proteína C Asociada a Surfactante Pulmonar/efectos de los fármacos , Proteína C Asociada a Surfactante Pulmonar/genética , ARN Mensajero/efectos de los fármacos , ARN Mensajero/metabolismo , Distribución Aleatoria , Respiración Artificial , OvinosRESUMEN
Allergic rhinitis (AR) is a chronic respiratory inflammatory disease. Glycyrrhizin is a main bioactive component of the licorice root extract and exhibits anti-inflammatory activity. However, the role of glycyrrhizin in AR has not been studied. The aim of the present study was to investigate the effect of glycyrrhizin on histamine-induced human nasal epithelial cells (HNEpCs). Here, we found that glycyrrhizin (20 or 40⯵M) inhibited histamine-induced the mRNA expression and secretion of mucin 5 subtype AC (MUC5AC), interleukin (IL)-6 and IL-8 in HNEpCs. The expression levels of aquaporin 5 (AQP5) and phosphorylated cyclic adenosine monophosphate-responsive element binding protein (p-CREB) were decreased by histamine in HNEpCs and increased in cells treated with glycyrrhizin. The glycyrrhizin treatment inhibited histamine-induced expressions of p-NF-κB p65 and p-IκBα in HNEpCs, indicating that glycyrrhizin inhibited the activation of NF-κB pathway in histamine-induced HNEpCs. In addition, inhibition of the NF-κB pathway exhibited the similar effect with glycyrrhizin on histamine-induced HNEpCs. In summary, the results showed that glycyrrhizin reversed the effect of histamine on MUC5AC expression, inflammatory cytokine production, and AQP5 expression in HNEpCs, and the NF-κB pathway was involved in the effect. Glycyrrhizin might be used for complementary and alternative therapeutics of AR.
Asunto(s)
Acuaporina 5/efectos de los fármacos , Citocinas/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Ácido Glicirrínico/farmacología , Mucina 5AC/genética , Mucosa Nasal/efectos de los fármacos , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Antiinflamatorios/farmacología , Acuaporina 5/metabolismo , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Histamina/metabolismo , Humanos , Interleucina-6/metabolismo , Interleucina-8/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Transducción de Señal/efectos de los fármacos , Quinasa de Factor Nuclear kappa BRESUMEN
Aquaporin-5 (AQP5) is a member of the water channel protein family. Although AQP5 has been shown to be present in sweat glands, the presence or absence of regulated intracellular translocation of AQP5 in sweat glands remains to be determined. In this article, recent findings on AQP5 in sweat glands are presented. (1) Immunoreactive AQP5 was detected in the apical membranes and the intercellular canaliculi of secretory coils, and in the basolateral membranes of the clear cells in human eccrine sweat glands. (2) AQP5 rapidly concentrated at the apical membranes during sweating in mouse sweat glands. (3) Treatment of human AQP5-expressing Madin-Darby canine kidney cells with calcium ionophore A23187 resulted in a twofold increase in the AQP5 level in the apical membranes within 5 min. (4) Anoctamin-1, a calcium-activated chloride channel was detected in the apical membranes and it completely colocalized with AQP5 in the apical membranes in mouse sweat glands. AQP5 may be involved in sweating and its translocation may help to increase the water permeability of the apical membranes of sweat glands. AQP5 is a potential target molecule for the design of a sweat-modulating drug.
Asunto(s)
Acuaporina 5/fisiología , Glándulas Sudoríparas/fisiología , Sudoración/fisiología , Animales , Anoctamina-1 , Acuaporina 5/efectos de los fármacos , Transporte Biológico , Calcimicina/farmacología , Ionóforos de Calcio/farmacología , Membrana Celular/metabolismo , Canales de Cloruro/metabolismo , Perros , Humanos , Células de Riñón Canino Madin Darby , Ratones , Glándulas Sudoríparas/metabolismoRESUMEN
Ovalbumin (OVA)-induced asthma in mouse lungs causes changes in the mRNA and protein levels of aquaporins (AQPs). AQP expression was examined in the presence of various anti-asthmatic agents, including dexamethasone, ambroxol, and terbutaline. The influence of these agents on OVA-induced airway inflammation was also evaluated. The mRNA expression levels of AQP1, 4, and 5 were significantly reduced and that of AQP3 was significantly increased 24h after the last OVA exposure. The protein levels of AQP1, 3, and 5 mirrored the mRNA expression profiles, but AQP4 did not exhibit any changes. Only the mRNA and protein expression levels of AQP1 and AQP5 were significantly increased by these three anti-asthmatic agents. Dexamethasone and ambroxol improved the eosinophil infiltration, mucus secretion, and pulmonary edema caused by OVA, but terbutaline only alleviated pulmonary edema. These results indicate that AQP1 and AQP5 are closely related to pulmonary edema but not to eosinophil infiltration or mucus secretion during asthma. Anti-asthmatic agents could alleviate pulmonary edema through upregulating the expression of AQP1 and AQP5 in mouse lungs that have OVA-induced asthma.
Asunto(s)
Antiasmáticos/farmacología , Acuaporina 1/metabolismo , Asma/complicaciones , Edema Pulmonar/tratamiento farmacológico , ARN Mensajero/efectos de los fármacos , Ambroxol/uso terapéutico , Animales , Acuaporina 1/efectos de los fármacos , Acuaporina 5/efectos de los fármacos , Acuaporina 5/genética , Asma/tratamiento farmacológico , Dexametasona/uso terapéutico , Pulmón/efectos de los fármacos , Pulmón/patología , Ratones , Edema Pulmonar/patología , Terbutalina/uso terapéutico , Regulación hacia Arriba/efectos de los fármacos , Regulación hacia Arriba/fisiologíaRESUMEN
OBJECTIVE: Abnormal expression of aquaporin 5 (AQP5) is associated with ovarian cancer infiltration, metastasis and angiogenesis. AQP 5 expression and apoptosis have been shown to be closely related to nuclear transcription factor NF-κB. In this study, we investigated the inhibition of cell proliferation and the induction of apoptosis by Epigallocatechin gallate (EGCG), a potential anti-cancer drug, in the ovarian cancer cell line SKOV3 as well as the effect of EGCG on AQP5 expression and its possible mechanisms. METHODS: SKOV3 cells were treated with different concentrations of EGCG and the NF-κB-specific inhibitor pyrrolidine dithiocarbamate (PDTC) for different times. Cell proliferation was determined using the MTT assay, cell apoptosis was evaluated using the DNA ladder assay, the expression of AQP5, NF-κB p65 and IκBα was detected by immunohistochemistry, western blot analysis and RT-PCR, and the correlation of these protein expression was analyzed. RESULTS: With increasing concentrations of EGCG and prolonged treatment times, the growth inhibition rate of SKOV3 cells gradually increased in a dose- and time-dependent manner. The expression of AQP5 and nuclear p65 and IκBα was significantly decreased (P < 0.01). The cytoplasmic expression of IκBα gradually increased (P < 0.05), and the apoptosis of SKOV3 cells was induced as evidenced by typical fragmentation pattern in a DNA ladder assay. With increasing concentrations of PDTC and prolonged treatment times, the protein and mRNA levels of AQP5 in SKOV3 cells decreased (P < 0.01). In addition, the growth inhibition rate of SKOV3 cells significantly increased in a dose- and time-dependent manner. CONCLUSIONS: EGCG inhibited the proliferation and induced the apoptosis of ovarian cancer SKOV3 cells. EGCG also down-regulated expression of AQP5, which may inhibit tumor growth and be associated with nuclear transcription factor NF-κB.
Asunto(s)
Anticarcinógenos/farmacología , Apoptosis/efectos de los fármacos , Acuaporina 5/metabolismo , Catequina/análogos & derivados , Proliferación Celular/efectos de los fármacos , Neoplasias Ováricas/metabolismo , ARN Mensajero/metabolismo , Análisis de Varianza , Antioxidantes/farmacología , Acuaporina 5/efectos de los fármacos , Catequina/farmacología , Línea Celular Tumoral , Membrana Celular/metabolismo , Núcleo Celular/metabolismo , Citoplasma/metabolismo , Relación Dosis-Respuesta a Droga , Regulación hacia Abajo , Femenino , Humanos , Proteínas I-kappa B/metabolismo , Inhibidor NF-kappaB alfa , Neoplasias Ováricas/patología , Pirrolidinas/farmacología , Tiocarbamatos/farmacología , Factor de Transcripción ReIA/metabolismoRESUMEN
The water channel aquaporin 5 (AQP5) seems to play a key role in salivary fluid secretion and appears to be critical in the cell volume regulation of acinar cells. Recently, the cation channel transient potential vanilloid receptor 4 (TRPV4) was shown to be functionally connected to AQP5 and also to cell volume regulation in salivary glands. We used the Simian virus 40 (SV40) immortalized cell line SMG C10 from the rat submandibular salivary gland to investigate the effect of ATP and the neurotransmitter analogue carbachol on Ca(2+) signalling and cell volume regulation, as well as the involvement of TRPV4 in the responses. We used fura-2-AM imaging, cell volume measurements, and western blotting. Both carbachol and ATP increased the concentration of intracellular Ca(2+), but no volume changes could be measured. Inhibition of TRPV4 with ruthenium red impaired both ATP- and carbachol-stimulated Ca(2+) signals. Peak Ca(2+) signalling during hyposmotic exposure was significantly decreased following inhibition of TRPV4, while the cells' ability to volume regulate appeared to be unaffected. These results show that in the SMG C10 cells, simulation of nervous stimulation did not induce cell swelling, although the cells had intact volume regulatory mechanisms. Furthermore, even though Ca(2+) signals were not needed for this volume regulation, TRPV4 seems to play a role during ATP and carbachol stimulation.
Asunto(s)
Señalización del Calcio/efectos de los fármacos , Colinérgicos/farmacología , Purinas/farmacología , Glándula Submandibular/efectos de los fármacos , Adenosina Trifosfato/farmacología , Animales , Acuaporina 5/efectos de los fármacos , Atropina/farmacología , Carbacol/farmacología , Técnicas de Cultivo de Célula , Línea Celular Transformada , Tamaño de la Célula/efectos de los fármacos , Agonistas Colinérgicos/farmacología , Colorantes Fluorescentes , Fura-2/análogos & derivados , Antagonistas Muscarínicos/farmacología , Presión Osmótica/fisiología , Antagonistas del Receptor Purinérgico P2 , Fosfato de Piridoxal/análogos & derivados , Fosfato de Piridoxal/farmacología , Ratas , Receptores Purinérgicos P2X , Rojo de Rutenio/farmacología , Glándula Submandibular/citología , Suramina/farmacología , Canales Catiónicos TRPV/antagonistas & inhibidores , Canales Catiónicos TRPV/efectos de los fármacosRESUMEN
Vanilloid receptor-1 (VR1) was originally found in the nervous system. Recent evidence indicates that VR1 is also expressed in various cell types. We hypothesized that VR1 exists in the human submandibular gland (SMG) and is involved in regulating salivary secretion. VR1 mRNA and protein were expressed in human SMGs and a human salivary intercalated duct cell line. VR1 was mainly located in serous acinar and ductal cells, but not in mucous acinar cells. Capsaicin, an agonist of VR1, increased intracellular free calcium, enhanced phosphorylation of extracellular signal-regulated kinase, and induced the trafficking of aquaporin 5 (AQP5) from the cytoplasm to the plasma membrane. These effects were abolished by pre-treatment with the VR1 antagonist capsazepine. Furthermore, capsaicin cream applied to the skin covering the submandibular area increased salivary secretion. These findings indicated that a functional VR1 is expressed in the human SMG and is involved in regulating salivary secretion by mediating AQP5 trafficking.
Asunto(s)
Glándula Submandibular/citología , Canales Catiónicos TRPV/análisis , Adulto , Anciano , Acuaporina 5/efectos de los fármacos , Calcio/análisis , Capsaicina/análogos & derivados , Capsaicina/farmacología , Línea Celular , Membrana Celular/efectos de los fármacos , Citoplasma/efectos de los fármacos , Quinasas MAP Reguladas por Señal Extracelular/efectos de los fármacos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Membrana Mucosa/citología , Fosforilación , Saliva/efectos de los fármacos , Saliva/metabolismo , Conductos Salivales/citología , Membrana Serosa/citología , Canales Catiónicos TRPV/agonistas , Canales Catiónicos TRPV/antagonistas & inhibidores , Adulto JovenRESUMEN
Overexpression of several aquaporins has been reported in different types of human cancer but the role of AQPs in human carcinogenesis has not yet been clearly defined. Here, we demonstrate that ectopic expression of human AQP5 (hAQP5), a water channel expressed in lung, salivary glands, and kidney, induces many phenotypic changes characteristic of transformation both in vitro and in vivo. Furthermore, the cell proliferative ability of AQP5 appears to be dependent upon the phosphorylation of a cAMP-protein kinase (PKA) consensus site located in a cytoplasmic loop of AQP5. In addition, phosphorylation of the PKA consensus site was found to be phosphorylated preferentially in tumors. These findings altogether indicate that hAQP5 plays an important role in human carcinogenesis and, furthermore, provide an attractive therapeutic target.
Asunto(s)
Acuaporina 5/metabolismo , Transformación Celular Neoplásica , Neoplasias/tratamiento farmacológico , Neoplasias/metabolismo , Proteínas Proto-Oncogénicas/metabolismo , Animales , Acuaporina 5/efectos de los fármacos , Acuaporina 5/genética , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Transformación Celular Neoplásica/genética , Humanos , Ratones , Células 3T3 NIH , Neoplasias/genética , Fosforilación , Proteínas Proto-Oncogénicas/efectos de los fármacos , ARN Interferente Pequeño/farmacología , Regulación hacia Arriba/genéticaRESUMEN
Aquaporins (AQPs) are membrane channel proteins that play roles in the regulation of water permeability in many tissues. AQP1 and AQP5 expressed in lung provide the principal route for osmotically driven water transport. In the airways, AQP3 and AQP4 facilitate water transport. Dexamethasone and ambroxol are often used to treat patients with pulmonary diseases accompanied by airway hypersecretion. The role of AQPs in these effective treatments has not been addressed. In this study, we analyzed the expression of AQPs in a human airway epithelial cell line (A549 cells) and showed that AQP3 and 5, but not AQP1 and 4, were expressed in A549 cells. Both dexamethasone and ambroxol stimulated the expression of AQP3 and 5 at the mRNA and protein levels. The data suggest potential roles of AQP3 and 5 in the regulation of airway hypersecretion, perhaps ultimately providing a target for treating such diseases.
Asunto(s)
Adenocarcinoma/metabolismo , Acuaporina 3/metabolismo , Acuaporina 5/metabolismo , Células Epiteliales/metabolismo , Neoplasias Pulmonares/metabolismo , Adenocarcinoma/tratamiento farmacológico , Ambroxol/farmacología , Acuaporina 1/efectos de los fármacos , Acuaporina 1/genética , Acuaporina 1/metabolismo , Acuaporina 3/efectos de los fármacos , Acuaporina 3/genética , Acuaporina 4/efectos de los fármacos , Acuaporina 4/genética , Acuaporina 4/metabolismo , Acuaporina 5/efectos de los fármacos , Acuaporina 5/genética , Dexametasona/farmacología , Células Epiteliales/citología , Células Epiteliales/efectos de los fármacos , Expectorantes/farmacología , Humanos , Inmunohistoquímica , Neoplasias Pulmonares/tratamiento farmacológico , ARN Mensajero/análisis , Mucosa Respiratoria/citología , Mucosa Respiratoria/efectos de los fármacos , Mucosa Respiratoria/metabolismo , Células Tumorales CultivadasRESUMEN
The aim of this study was to clarify the effects of the muscarinic receptor agonist, cevimeline, on saliva flow and expression of aquaporin5 (AQP5) in submandibular gland after X-ray irradiation. Using a previously established radiation-induced xerostomia model mouse, saliva flow from at 7 days before irradiation to at 28 days after irradiation was investigated in mice that were treated with cevimeline before or after irradiation. Radiation caused a significant decrease in saliva flow compared with nonirradiated salivary glands. Cevimeline post-treatment also caused a significant decrease in saliva flow. In contrast, cevimeline pre-treatment did not significantly decrease saliva flow. Expression of AQP5 fluorescent intensity and mRNA were also analyzed. Irradiation significantly decreased expression of AQP5 in submandibular gland. However, pre-treatment with cevimeline prevented this decrease in AQP5 expression. These data suggest that pretreatment with cevimeline prevents radiation-induced xerostomia and radiation-induced decrease in expression of AQP5 in submandibular gland.